Zelboraf Prescribing information

Zelboraf prescribing information fulfills the requirement of supplying all data which is essential for the doctor to be acquainted with, before prescribing and initiating the patient’s medication. It holds gargantuan significance because the manufacturer provides this literature to guarantee a patient’s safety and drug’s efficacy with the course of treatment.

According to zelboraf prescribing information, mainly, the drug is prescribed for patients having BRAF V600E mutation positive metastatic melanoma, which cannot be eliminated by operative techniques.

The zelboraf prescribing information states the recommended dose of drug as 960mg (4 tablets of 240 mg) twice a day, with an interval of 12 hours approximately. Patients who are unable to resist the side effects associated with the normal dose are therefore advised by the zelboraf prescribing information to minimize the dose; nevertheless the lowest effective dose of Zelboraf is 480 mg twice a day.

Zelboraf prescribing information provided to doctors and oncologists also comprises of information with regard to drug’s adverse effects, allergy and drug interactions. Oncologists are advised to have a detailed examination of the patient before the treatment and monitor his/her all vital parameters during the course of treatment. Common untoward effects of the drug mentioned in zelboraf prescribing information are
• Urticaria
• Arthralgia
• Photosensitivity
• Alopecia
• Nausea
• Papiloma
• Pruritis.
Zelboraf prescribing information assists the prescriber in selecting the accurate dose for the diagnosed condition and in managing any complications owing to the use of medication.

Zelboraf prescribing information highlights the anomalies and concerns associated with the use of drug by a specific population of patients such as pregnant and nursing mothers, pediatrics, geriatrics and patients with kidney and hepatic impairment

Drug manufacturers (Roche ® Plexxikon® etc) provide zelboraf prescribing information to doctors and oncologists in order to enhance their awareness with the novel drug ,it encompasses data from drug’s description, pharmacological properties, toxicology, clinical studies, trial record, and precautions which are deemed compulsory to be followed by the patient to minimize the untoward effects of the drug, storage information, overdose precautions.

Zelboraf prescribing information also gives suggestions to patients who happen to miss a dose and contains details of dose modifications. Confirmation of BRAFV600E mutation-positive melanoma as detected by an FDA-approved test is required for selection of patients for Zelboraf therapy. The manufacturers provide this literature for authorized prescribers to ensure safe use of drug in patients with melanoma.

The manufacturers provide this literature for authorized prescribers to ensure safe use of drug in patients with melanoma. The zelboraf prescribing information pdf from the manufacturers is given here: http://www.gene.com/gene/news/news-events/zelboraf/pi.pdf